Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Eligibility Criteria

From: Association between furosemide in premature infants and sensorineural hearing loss and nephrocalcinosis: a systematic review

Patient/Population Infant < 37 weeks completed gestational age
Intervention ≥1 dose of furosemide (IV or PO) during hospitalization in the neonatal intensive care unit
Control Infant < 37 weeks completed gestational age without exposure to furosemide
Outcomes sensorineural hearing loss; nephrocalcinosis/nephrolithiasis
Study Design clinical trials, retrospective or prospective cohort studies, case-control studies